Baker Bros. Advisors Adds $5M in Eikon Therapeutics, Inc. ($EIKN)
Key Points
- Wall Street's consensus rating on $EIKN is Buy and an average price target of $24.80.
- $EIKN last traded around $8.54.
Baker Bros. Advisors acquired a new position in Eikon Therapeutics, Inc. ($EIKN), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 555,555 shares of Eikon Therapeutics, Inc.. Baker Bros. Advisors's holdings in Eikon Therapeutics, Inc. were worth $4.74 million as of its most recent filing.
Eikon Therapeutics, Inc. ($EIKN) Stock
Eikon Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.